<DOC>
	<DOCNO>NCT00023335</DOCNO>
	<brief_summary>Primary Objective : To compare , completion follow-up phase , clinical bacteriologic relapse rate associate two study regimen . Secondary Objectives : To compare clinical bacteriologic failure rate two study regimen completion study phase therapy . To compare clinical bacteriologic response rate two study regimen among patient begin study phase therapy sign symptom tuberculosis culture positive M. tuberculosis . To compare toxicity associate two study regimen compare discontinuation rate due adverse event occurrence rate sign symptom associated adverse event study phase therapy . To compare mortality rate two study regimen . To compare rate completion therapy within 22 week two study regimen . To compare rate development drug-resistant tuberculosis two study regimen among study patient classify treatment failure relapse . To compare performance characteristic two study regimen small subset HIV seropositive patient . To compare attitude beliefs participation study patient complete study therapy fail complete study therapy .</brief_summary>
	<brief_title>TBTC Study 22 : Efficacy Once-Weekly Rifapentine Isoniazid Treatment Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Culturepositive , drugsusceptible pulmonary tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>